Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
NCT03861091Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lung neoplasm comparing Risedronate with Matching Placebo (2 arms). Primary endpoint: Changes in Mean Cortical Thickness at 3 months. Started Jul 2019; status: completed.
02
Drugs
risedronate
03
Conditions
lung neoplasm
Beyond the preview
Go deeper on NCT03861091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861091.